New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
13:30 EDTBCRX, DYAXBioCryst data has favorable read through for Dyax, says Jefferies
After Biocryst (BCRX) reported positive data from a trial evaluating BCX4161 in hereditary angioedema, Jefferies said the study results point to higher odds for the success of Dyax's (DYAX) DX-2930, which has a similar pathway and is being developed as a prophylactic treatment for HAE. The firm maintains its Buy rating and $13.00 price target on Dyax.
News For DYAX;BCRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
13:24 EDTBCRXLiberia, U.S. begin ZMapp ebola trial
In partnership with the Liberian government, the National Institute of Allergy and Infectious Diseases launched a clinical trial to obtain safety and efficacy data on the investigational drug ZMapp as a treatment for Ebola virus disease. The study may be expanded to test ZMapp against other treatments which may also include the following: Tekmira siRNA from Tekmira Pharmaceuticals (TKMR), Favipiravir from Toyama Chemical, BCX4430 from BioCryst (BCRX), and AVI-7537 from Sarepta (SRPT). The trial is expected to conclude in December 2016.
February 24, 2015
07:10 EDTDYAXDyax sees FY15 Kalbitor net sales $60M-$70M
Subscribe for More Information
07:08 EDTDYAXDyax reports Q4 EPS (2c), consensus (4c)
Reports Q4 revenue $26M, consensus $19.9M.
February 20, 2015
07:08 EDTDYAXAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 18, 2015
06:58 EDTBCRXBioCryst sees FY15 operating expenses $75M-$95M
Subscribe for More Information
06:57 EDTBCRXBioCryst reports Q4 EPS (16c), consensus (21c)
Reports Q4 revenue $5.4M, consensus $3.64M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use